Please ensure Javascript is enabled for purposes of website accessibility
Home / Information / Highlights

The pET Expression System: Design Logic and Selection Strategy
2026-03-04 853

The pET Expression System: Design Logic and Selection Strategy

The pET vector series, originally developed by Novagen (now part of Merck), represents one of the most widely adopted T7-based expression platforms in Escherichia coli.

Its popularity stems not from a single superior plasmid design, but from a modular, tightly regulated, and high-output transcription system.

Mechanistic Foundation of the pET System

T7 Promoter-Driven Transcription

Target genes in pET vectors are placed under the control of the bacteriophage T7 promoter, which is recognized exclusively by T7 RNA polymerase.

Key characteristics include:

  • Extremely high transcription rate
  • Strong promoter specificity
  • Minimal cross-recognition of host promoters

This ensures robust transcription once T7 polymerase is available.

Dual-Level Induction Mechanism

The pET system operates through a two-tier control process:

  1. IPTG induces expression of T7 RNA polymerase from the host chromosome (e.g., DE3 lysogen).
  2. T7 RNA polymerase subsequently drives transcription from the plasmid-borne T7 promoter.

This amplification mechanism accounts for the exceptionally high expression levels observed in pET systems.

Structural Modules of pET Vectors

Key functional elements include:

  • T7 promoter and lac operator
  • Multiple cloning site (MCS)
  • Fusion tags (His, GST, MBP, Trx, SUMO, etc.)
  • Protease cleavage sites
  • Antibiotic resistance markers (Amp or Kan)
  • pBR322-derived origin of replication
  • Optional f1 origin (in "+" variants) for single-stranded DNA production

Host Dependency

pET vectors require host strains expressing T7 RNA polymerase, such as:

  • BL21(DE3)
  • C41(DE3)
  • C43(DE3)

Standard cloning strains (e.g., DH5α) do not support expression.

Vector Selection Strategy

Selection should be guided by:

  • Protein solubility
  • Toxicity
  • Downstream purification requirements
  • Scale of production
Expression outcome is determined by the combination of: Vector × Host Strain × Culture Condition.
Systematic optimization is strongly recommended for preparative-scale production.

AntibodySystem Recombinant Proteins

Catalog Product Name
YHJ70101 Recombinant Human CD274/PD-L1/B7-H1 Protein, N-His
YHJ63901 Recombinant Human CD93 Protein, N-GST
YHE07701 Recombinant Human IL13 Protein, N-His
YHJ72801 Recombinant Human IL36RN Protein, N-His
YHA41901 Recombinant Human NPC1 Protein, N-His
YHB15401 Recombinant Human PDCD6 Protein, N-His
YHG71101 Recombinant Human PDE1C Protein, N-His
YHB40701 Recombinant Human PDE5A Protein, N-His
YHC06301 Recombinant Human PDGFA Protein, N-His
YHC33501 Recombinant Human PDHA1 Protein, N-His
YHH02301 Recombinant Human PDK1 Protein, N-His
YHE22001 Recombinant Human SNCA Protein, N-His
YXX05601 Recombinant Protein A/SPA Protein, C-His
EVV00314 Recombinant SARS-CoV-2 RBD Protein, C-His
YVV02101 Recombinant SARS-CoV-2 ORF7a/Protein U122 Protein, N-His

 

Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only